Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
Antiprogestin which derives from Norethisterone, Mifepristone is a cortisol receptor blocker used to treat Cushing's syndrome and to terminate pregnancies up to 50-70 days' gestation.
Its high plasma protein-binding capacity and large volume of distribution (Sarkar 2002) explains that excretion into breast milk is clinically non-significant. It achieves very low levels in breast milk at a maternal dose of 600 mg or undetectable at maternal dose of 200 mg. (Sääv 2010)
The punctual use of mifepristone does not contraindicate breastfeeding. (LactMed, Bettahar 2016)
When used with semi-experimental purposes due to its anti-androgenic and antiglucocorticoid properties a continuous administration and / or large doses is required. There is no experience in connection with breastfeeding. Those pathologies in which it is often used on a continuous basis by themselves are not compatible with breastfeeding.